Uso de cloroquina, azitromicina e ivermectina durante a pandemia da COVID-19: Uma revisão integrativa

Felipe Reis; Jailton de Jesus  Rocha Junior; Angélica Augusta Grigoli  Dominato

doi:10.33448/rsd-v12i13.44225

Autores/as

Felipe Reis Universidade do Oeste Paulista https://orcid.org/0009-0008-2539-3046
Jailton de Jesus Rocha Junior Universidade do Oeste Paulista https://orcid.org/0009-0004-4640-4462
Angélica Augusta Grigoli Dominato Universidade do Oeste Paulista https://orcid.org/0000-0001-6298-5106

DOI:

https://doi.org/10.33448/rsd-v12i13.44225

Palabras clave:

Azitromicina; Cloroquina; Ivermectina; COVID-19; Efectos adversos.

Resumen

Durante la pandemia de COVID-19, la comunidad científica buscó con vehemencia medicamentos que pudieran ayudar a tratar la enfermedad en cuestión. Medicamentos como cloroquina, azitromicina e ivermectina se utilizaron como automedicación, antes de confirmarse su eficacia contra el virus y la enfermedad. Después de poco más de dos años desde el inicio de la pandemia mundial de COVID, la forma en que cuidamos nuestra salud todavía suscita hipótesis entre la población sobre las diferentes formas correctas de afrontar la enfermedad, afirmando que diferentes enfoques serían efectivos o no. El objetivo reunió evidencia sobre la farmacocinética, el mecanismo de acción propuesto en COVID-19, los efectos adversos, la eficacia y seguridad de cloroquina/hidroxicloroquina, azitromicina e ivermectina para la profilaxis y el tratamiento de COVID-19. La metodología utilizada fue una revisión integradora, que siguió las recomendaciones de la guía PRISMA adaptada. La búsqueda bibliográfica se realizó en las bases de datos PubMed, LILACS y MEDLINE. Se realizó un análisis crítico para determinar el rigor metodológico de los estudios, a partir de la valoración del nivel de evidencia científica. Los resultados mostraron que el uso de hidroxicloroquina, cloroquina, azitromicina o ivermectina, en formas leves o graves de COVID-19, tanto en tratamiento como en profilaxis, no demostró ningún beneficio en la reducción de la mortalidad, las hospitalizaciones u otros resultados desfavorables, sin limitar la transmisión. virus ni impedir la instalación de la infección. Concluyendo que el uso de estos medicamentos antes mencionados como medidas profilácticas y terapéuticas para el COVID-19 está contraindicado, debido a la falta de evidencia favorable consistente y los numerosos reportes de resultados adversos en dichos tratamientos.

Citas

Axfors, C., Schmitt, A. M., Janiaud, P., van’t Hooft, J., Abd-Elsalam, S., Abdo, E. F., Abella, B. S., Akram, J., Amaravadi, R. K., Angus, D. C., Arabi, Y. M., Azhar, S., Baden, L. R., Baker, A. W., Belkhir, L., Benfield, T., Berrevoets, M. A. H., Chen, C. P., Chen, T. C., & Hemkens, L. G. (2021). Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-22446-z

Barbosa, A. N., Chebabo, A., Starling, C., Pérez, C., Cunha, C. A., de Luna, D., Nunes, E. P., Zambrano, G., Ferreira, J. C., Croda, J., Falavigna, M., Gomes-da-Silva, M. M., Thormann, M., Cimerman, S., Parahiba, S. M., Tanni, S., Bernardo, W. M., & Rodriguez-Morales, A. J. (2023). Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Em Annals of Clinical Microbiology and Antimicrobials 22(1). https://doi.org/10.1186/s12941-023-00623-w

Das, R., Behera, B., Mishra, B., & Naik, S. (2020). Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-Analysis. Em Indian Journal of Medical Microbiology. 38(3–4), 265–272. https://doi.org/10.4103/ijmm.IJMM_20_330

Dauner, D. G., & Dauner, K. N. (2021). Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic. Journal of the American Pharmacists Association, 61(3), 293–298. https://doi.org/10.1016/j.japh.2021.01.007

Della Porta, A., Bornstein, K., Coye, A., Montrief, T., Long, B., & Parris, M. A. (2020). Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. Em American Journal of Emergency Medicine. 38(10), 2209–2217. https://doi.org/10.1016/j.ajem.2020.07.030

Ferreira, P. M. P., de Sousa, R. W. R., Dittz, D., E Sousa, J. M. de C., Torres-Leal, F. L., & Bezerra, D. P. (2023). Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. Brazilian Journal of Pharmaceutical Sciences, 59. https://doi.org/10.1590/s2175-97902023e21067

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1). https://doi.org/10.1016/j.ijantimicag.2020.105949

Gumilang, R. A., Siswanto, Anggraeni, V. Y., Trisnawati, I., Budiono, E., & Hartopo, A. B. (2021). QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia. Journal of Arrhythmia, 37(5), 1184–1195. https://doi.org/10.1002/joa3.12623

Heidary, F., & Gharebaghi, R. (2020). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. Em Journal of Antibiotics (Vol. 73, Número 9, p. 593–602). Springer Nature. https://doi.org/10.1038/s41429-020-0336-z

Izcovich, A., Peiris, S., Ragusa, M., Tortosa, F., Rada, G., Aldighieri, S., & Reveiz, L. (2022). Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin’s suggested benefits are mainly based on potentially biased results. Journal of Clinical Epidemiology, 144, 43–55. https://doi.org/10.1016/j.jclinepi.2021.12.018

Kamel, A. M., Monem, M. S. A., Sharaf, N. A., Magdy, N., & Farid, S. F. (2022). Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. Em Reviews in Medical Virology. 32(1). https://doi.org/10.1002/rmv.2258

Kashour, Z., Riaz, M., Garbati, M. A., AlDosary, O., Tlayjeh, H., Gerberi, D., Hassan Murad, M., Rizwan Sohail, M., Kashour, T., & Tleyjeh, I. M. (2021). Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 76(4), 30–42. https://doi.org/10.1093/JAC/DKAA403

Marcolino, M. S., Meira, K. C., Guimarães, N. S., Motta, P. P., Chagas, V. S., Kelles, S. M. B., de Sá, L. C., Valacio, R. A., & Ziegelmann, P. K. (2022). Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infectious Diseases, 22(1). https://doi.org/10.1186/s12879-022-07589-8

Meo, S. A., Zaidi, S. Z. A., Shang, T., Zhang, J. Y., Al-Khlaiwi, T., Bukhari, I. A., Akram, J., & Klonoff, D. C. (2020). Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. Journal of King Saud University - Science, 32(7), 3159–3166. https://doi.org/10.1016/j.jksus.2020.09.002

Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Gentile, N., Collins, S., McCarthy, M. W., Jayaweera, D., Castro, M., Sulkowski, M., McTigue, K., Thicklin, F., Felker, G. M., Ginde, A. A., Bramante, C. T., Slandzicki, A. J., Gabriel, A., Shah, N. S., Lenert, L. A., & Hernandez, A. F. (2022). Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA, 328(16), 1595–1603. https://doi.org/10.1001/jama.2022.18590

Nicol, M. R., Joshi, A., Rizk, M. L., Sabato, P. E., Savic, R. M., Wesche, D., Zheng, J. H., & Cook, J. (2020). Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. Em Clinical Pharmacology and Therapeutics. 108(6), 1135–1149.

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology, 134, 178–189. https://doi.org/10.1016/j.jclinepi.2021.03.001

Rezai, M. S., Ahangarkani, F., Hill, A., Ellis, L., Mirchandani, M., Davoudi, A., Eslami, G., Roozbeh, F., Babamahmoodi, F., Rouhani, N., Alikhani, A., Najafi, N., Ghasemian, R., Mehravaran, H., Hajialibeig, A., Navaeifar, M. R., Shahbaznejad, L., Rahimzadeh, G., Saeedi, M., & Valadan, R. (2022). Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.919708

Sekhavati, E., Jafari, F., SeyedAlinaghi, S. A., Jamalimoghadamsiahkali, S., Sadr, S., Tabarestani, M., Pirhayati, M., Zendehdel, A., Manafi, N., Hajiabdolbaghi, M., Ahmadinejad, Z., Kouchak, H. E., Jafari, S., Khalili, H., Salehi, M., Seifi, A., Golestan, F. S., & Ghiasvand, F. (2020). Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. International Journal of Antimicrobial Agents, 56(4). https://doi.org/10.1016/j.ijantimicag.2020.106143

Shirazi, F. M., Mirzaei, R., Nakhaee, S., Nejatian, A., Ghafari, S., & Mehrpour, O. (2022). Repurposing the drug, ivermectin, in COVID-19: toxicological points of view. Em European Journal of Medical Research. 27(1). https://doi.org/10.1186/s40001-022-00645-8

Tavares De Souza, M., Dias Da Silva, M., & De Carvalho, R. (2010). Revisão integrativa: o que é e como fazer Integrative review: what is it? How to do it? (Vol. 8, Número 1).

Tleyjeh, I. M., Kashour, Z., AlDosary, O., Riaz, M., Tlayjeh, H., Garbati, M. A., Tleyjeh, R., Al-Mallah, M. H., Sohail, M. R., Gerberi, D., Bin Abdulhak, A. A., Giudicessi, J. R., Ackerman, M. J., & Kashour, T. (2021). Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 5(1), 137–150. https://doi.org/10.1016/j.mayocpiqo.2020.10.005

Touret, F., & de Lamballerie, X. (2020). Of chloroquine and COVID-19. Em Antiviral Research (Vol. 177). https://doi.org/10.1016/j.antiviral.2020.104762

Ursi, E. S., & Gavão, C. M. (2006). Prevenção de lesões de pele no perioperatório: revisão integrativa da literatura. Revista Latino-Americana de Enfermagem, 14(1), 124–131. https://doi.org/10.1590/S0104-11692006000100017

Yao, X., Yan, X., Wang, X., Cai, T., Zhang, S., Cui, C., Wang, X., Hou, Z., Liu, Q., Li, H., Lin, J., Xiong, Z., & Liu, D. (2021). Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European Journal of Clinical Pharmacology, 77(4), 583–593. https://doi.org/10.1007/s00228-020-03032-6

Yuan, Y., Jiao, B., Qu, L., Yang, D., & Liu, R. (2023). The development of COVID-19 treatment. Em Frontiers in Immunology (Vol. 14). Frontiers Media S.A. https://doi.org/10.3389/fimmu.2023.1125246

Zaidi, A. K., & Dehgani-Mobaraki, P. (2022). The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. Em Journal of Antibiotics 75(2), 60–71. https://doi.org/10.1038/s41429-021-00491-6

Uso de cloroquina, azitromicina e ivermectina durante la pandemia COVID-19: Una revisión integrativa

Autores/as

DOI:

Palabras clave:

Resumen

Citas

Descargas

Publicado

Cómo citar

Número

Sección

Licencia

JOURNAL METRICS

Idioma

Enviar un artículo